Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

TERN - Terns Pharmaceuticals, Inc. Latest News | Finranks

Home

TERN

(TERN)

NMS – Real Time Price. Currency in USD

52.92

-0.25 (-0.47%)

At close: Mar 27, 2026, 4:00 PM EDT

52.93

+0.01 (0.02%)

After-hours: Mar 27, 2026, 7:44 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

Terns CEO Amy Burroughs talks cancer drug trial win

Press releases

Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Terns will receive $53.00 in cash for each share of Terns that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Terns Pharmaceuticals, Inc. (NASDAQ: TERN)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Terns Pharmaceuticals, Inc. (NASDAQ: TERN)

NEW YORK, March 25, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) related to its sale to Merck Sharp & Dohme LLC.

Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Terns (NASDAQ: TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

TERN Stock Alert: Halper Sadeh LLC is Investigating Whether Terns Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

TERN Stock Alert: Halper Sadeh LLC is Investigating Whether Terns Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) to Merck for $53.00 per share in cash. Halper Sadeh encourages Terns shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Terns and its board of directors violated the fed.